Australia - engleză - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 1.6 g - injection, solution - excipient ingredients: water for injections; human immunoglobulin a; glycine - evogam is indicated in adults and children for replacement therapy in: primary immunodeficiency disease (pid) and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - anti-d rho immunoglobulin, quantity: 250 iu; anti-d rho immunoglobulin, quantity: 10 mg/ml - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - rh(d) immunoglobulin is indicated for the prevention of rh sensitisation in rh(d)negative females at or below child bearing age.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - anti-d rho immunoglobulin, quantity: 625 iu; anti-d rho immunoglobulin, quantity: 30 mg/ml - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - indications as at 6 august 2002 : rh(d) immunoglobulin is indicated for the prevention of rh sensitisation in rh(d) negative females at or below child bearing age.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 0.06 g/ml - injection, solution - excipient ingredients: maltose - replacement therapy in adults and children: ?primary immunodeficiency diseases (pid). ?symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in adults and children: ?idiopathic thrombocytopenic purpura (itp) in patients at high risk of bleeding or prior to surgery to correct the platelet count. ?guillain-barr? syndrome (gbs). ?kawasaki disease.

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - human plasma protein >90% gamma globulin - powder and solvent for solution for infusion - 0.5 g/30 m gram(s)/millilitre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm. - immune sera and immunoglobulins: immunoglobulins, normal human, for intravascular administration - primary immunodeficiency syndromes (pid): congenital agammaglobulinaemia and hypogammaglobulinaemia common variable immunodeficiencies severe combined immunodeficiencies wiskott aldrich syndrome myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections children with congenital aids and recurrent infections

Australia - engleză - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - normal immunoglobulin, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dilute hydrochloric acid; sodium hydroxide; glycine; water for injections - replacement therapy in. * primary immunodeficiency diseases. * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation. * idiopathic thrombocytopenic purpura, in adults or children at high risk of bleeding or prior to surgery to correct the platelet count.. * guillain barre syndrome. * kawasaki disease.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - normal immunoglobulin, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dilute hydrochloric acid; sodium hydroxide; glycine; water for injections - replacement therapy in. * primary immunodeficiency diseases. * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation. * idiopathic thrombocytopenic purpura, in adults or children at high risk of bleeding or prior to surgery to correct the platelet count.. * guillain barre syndrome. * kawasaki disease.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - normal immunoglobulin, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dilute hydrochloric acid; sodium hydroxide; glycine; water for injections - replacement therapy in. * primary immunodeficiency diseases. * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation. * idiopathic thrombocytopenic purpura, in adults or children at high risk of bleeding or prior to surgery to correct the platelet count.. * guillain barre syndrome. * kawasaki disease.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - normal immunoglobulin, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dilute hydrochloric acid; sodium hydroxide; glycine; water for injections - replacement therapy in. * primary immunodeficiency diseases. * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation. * idiopathic thrombocytopenic purpura, in adults or children at high risk of bleeding or prior to surgery to correct the platelet count.. * guillain barre syndrome. * kawasaki disease.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 40 g - injection, solution - excipient ingredients: water for injections; proline - replacement therapy for primary immunodeficiency diseases (pid), myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy for idiopathic thrombocytopenic purpura (itp) in patients at high risk of bleeding or prior to surgery to correct the platelet count, guillain-barr syndrome (gbs), kawasaki disease, chronic inflammatory demyelinating polyneuropathy (cidp), multifocal motor neuropathy (mmn), myasthenia gravis (mg) exacerbations, lambert-eaton myasthenic syndrome (lems), stiff person syndrome (sps).